INTRODUCTION 42
Leishmaniasis is a non-contagious infectious disease caused by parasites of the genus Leishmania 43 and is usually transmitted by sandflies belonging to the genera Phlebotomus and Lutzomyia. 44
According to the species of Leishmania involved, the infection can affect the skin and mucous 45 membranes (cutaneous leishmaniasis -CL) or the internal organs (visceral leishmaniasis -VL) (1, 46 2). Official estimates point an annual incidence of approximately 300.000 VL cases and 1.0 million 47 CL cases worldwide (3). The basis of chemotherapy of leishmaniasis has its origin in the work of 48 Vianna (1912) , whom successfully treated a patient with emetic tartar (trivalent antimonial), a 49 formulation broadly used at that time to treat infectious diseases (4). From this empirical approach, 50 pentavalent antimonials were developed in the 1940´s and have saved thousands of lives for several 51 decades. Other drugs have been repositioned to treat leishmaniasis, such as amphotericin B, 52
pentamidine and more recently, miltefosine. Unfortunately, the therapeutic arsenal for leishmaniasis 53 has become quite limited and outdated. Antimonials have many toxic effects including cardiac, 54 hepatic, pancreatic and renal toxicity and should be used with caution and with clinical and 55 laboratory monitoring in patients with heart disease and liver disease (5). Miltefosine, the only oral 56 drug licensed, was the most important advance for the treatment of leishmaniasis in recent years. 57
Currently, it is the treatment of choice of program elimination of visceral leishmaniasis in India and 58 recently was approved by FDA for all forms of this disease, but cases of resistance have been 59
reported with increased failure of treatment (6-9). This scenario is a reflex of the difficulty of 60 launching new chemical entities as drugs for this disease. Radical innovation in drug discovery is a 61 time-and money-consuming process. Drug repositioning is an approach very used in the past and 62 that can be useful nowadays to address specific demands in areas of public health, such as neglected 63 and orphan diseases (10-12). This strategy offers the advantage of working with compounds that 64 have already been proved to be safe and to have a favorable pharmacokinetic profile in humans.further 1 hour, and formazan crystals were dissolved by adding 80 μl DMSO each well. The 94 reaction was analyzed in a spectrophotometer at a 570 nm wavelength. IC 50 values were obtained by 95 non-linear regression using Graphpad Prism 6 software (GraphPad Software, Inc., La Jolla, USA). 96
The fractional inhibitory concentration (FICI) for the analysis of synergy was calculated as follows: 97 FICI = IC 50 of drug A in combination/IC 50 of drug A alone + IC 50 of drug B in combination/IC 50 of 98 drug B alone. The interpretation of FICI, according to published guidelines are: synergy (FICI ≤ 99 0.5), antagonism (FICI > 4.0) and 'no interaction' (FICI > 0.5-4.0) (13). 100
Toxicity to macrophages. 101
Mouse peritoneal macrophages in 96-well plates were treated with ezetimibe, ketoconazole and 102 miconazole alone or in combination for 72 hours at 37°C. After this period, the cell viability was 103 evaluated by adding 10% tetrazolium salt (MTT) (5 mg/ml) to each well. The plates were incubated 104 at 37°C for another four hours, and the resulting formazan crystals were dissolved by adding 80 μl 105 DMSO to each well. The plates were then read at 570 nm. The results were expressed as the 106 percentage of viable cells compared to the untreated control. 107 Antiamastigote activity. Peritoneal macrophages from BALB/c mice were infected with 108 promastigotes of L. amazonensis (stationary growth phase) at a 3:1 parasite-to-macrophage ratio 109 and incubated for 4 h in Lab-Tek chambers (Nunc, Roskilde, Denmark) and kept at 37°C. After 4 110 hours, the chambers were washed, and the cultures were treated with the azole derivatives alone or 111 combined with ezetimibe in supplemented RPMI medium for 72 hours. For initial screening, the 112 concentration of drugs was fixed in 25 μM and a threshold of at least 50% of inhibition was 113 stablished. A drug-activity curve was done with ezetimibe, the only drug that reached the threshold, 114 with concentration ranging to 40 μM. In the association assays, the concentration of ezetimibe was 115 fixed at 20 μM, while the concentration of ketoconazole and miconazole ranged to 16 and 32 μM, 116 respectively. After incubation, the slides were stained, and the infection rate was determined by 117 counting under a light microscope. The infection rate was calculated using the formula: % infected 118 macrophages (14) . Briefly, samples were pelleted, and a solution of methanol, 121 chloroform and water (2:1:0.5 v/v) was added. After stirring the mixture for 1 hour, the samples 122 were centrifuged for 20 min at 3,000 rpm and the supernatant, containing the lipids was separated 123 from the precipitate. The precipitate was subjected to a second extraction under the same 124 conditions. The supernatants were combined, and chloroform/water (1:1 v/v) was added. After 40 125 seconds of stirring, the material was centrifuged (3.000 rpm/30 min) again. The lower layer 126 (organic) containing the lipids was then separated with the aid of a glass syringe and transferred to a 127 1.5 ml tube resistant to organic solvents (Axygen Scientific, Inc., Union City, CA, USA). The 128 solvent was evaporated under N 2 flux, and the lipids were analyzed by gas chromatography-mass 129 spectrometry (GC/MS), as described below. PBS (pH 7.5), and the sterols were extracted as described above. The samples were injected into a 134 GCMS -QP2010 Ultra Machine (Shimadzu Scientific Instruments, Tokyo, Japan). After injection, 135 the column temperature was maintained at 50°C for 1 minute and then increased to 270°C at a rate 136 of 10°C/min and finally to 300°C at a rate of 1°C/min. The flow of the carrier gas (He) was kept 137 constant at 1.1 ml/min. The temperatures of the injector and detector were 250°C and 280°C, 138 respectively (15). 139 The animals were treated 5 days per week in a total of 20 doses. Negative controls were also 148 similarly treated with PBS. The ear measurement was recorded once a week. After the treatment 149 period, the animals were euthanized for determination of parasite load and toxicological analysis. reaching to 20 μM. Ezetimibe also drew attention by provoking striking morphological changes on 162 the promastigotes of L. amazonensis. We observed that, in a concentration dependent manner, the 163 parasites became rounded and displayed multiple nuclei and flagellae, mainly at 40 μM ( Fig. 1) . 164
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Ezetimibe interferes with sterol biosynthesis in L. amazonensis. The morphological alterations 165 seen in ezetimibe-treated promastigotes induced us to investigate whether this drug interferes with 166 sterol biosynthesis of the parasite. Table 2 shows an analysis of the relative amount of each sterol 167 indicated by GC/MS. Promastigotes treated with miconazole, an inhibitor of C14-demethylase, 168
showed a decrease in the ergostane-derived sterols ergosta-5,7,24-trien-3β-ol (dehydroepisterol) (3) 169 and ergosta-7,24-dien-3β-ol (episterol) (4). Miconazole also induced the accumulation of 170 exogenous cholesterol collected from culture medium and an increase in the methylated sterols 171 14α-methylergosta-8,24(28)-dien-3β-ol (2) and 4α-14α-dimethylergosta-8,24(28)-dien-3β-ol 172 (obtusifoliol) (5). Treatment with ezetimibe also decreased dehydroepisterol and episterol (C14-173 demethylated sterols) and promoted the accumulation of cholesterol (1) and lanosterol (C14-174 methylated sterol) (7). We also observed the accumulation of an unknown sterol (6). 175
Ezetimibe potentiates the effect of azoles. Considering the significative alteration in sterol pattern 176 of the parasites after ezetimibe treatment, the antileishmanial activity of this drug was also 177 evaluated in combination with azoles (ketoconazole and miconazole) in promastigotes and 178 amastigotes of L. amazonensis. To graphically evaluate the interaction of ezetimibe with azoles in 179 promastigotes, the IC 50 of the drugs alone and in combination was plotted as isobolograms, and to 180 estimate the type of interaction (synergy, antagonism or neutral), the fractional inhibitory 181 concentration index (FICI) was calculated. As expected, miconazole and ketoconazole were active 182 against the promastigotes, with IC 50 of 2.5±0.1 and 2.7±0.1 μM, respectively. The IC 50 of the azoles 183 decreased when in combination with ezetimibe, generating fully concave isobolograms (Fig. 2) . The 184 calculation of FICI resulted in values of 0.4 for both combinations, confirming the synergism. Due 185 to the experimental difficulty of performing a "checkerboard" approach to draw isobolograms for 186 antiamastigote activity, we fixed the concentration of ezetimibe at the IC 50 (20 µM) (Fig. 3A) and 187 varied the concentration of the azoles to calculate the IC 90 (concentration that inhibits 90% of the 188 parasites) of the combination. When associated with ezetimibe, the IC 90 of ketoconazole and 189 miconazole were reduced from 11.3±0.2 μM and 11.5±0.1 μM to 4.14±0.3 μM and 8.25±0.2 μM, 190 respectively (Figs. 3B and C). Furthermore, ezetimibe, miconazole, ketoconazole alone or 191 combined showed no toxic effects to macrophages (Fig. 4A-E) . and miconazole that have normal morphology and a reduced parasite load (Fig. 5) . 194
For in vivo assays, BALB/c mice were infected with L. amazonensis and treated with 195 ezetimibe (10 mg/kg/day) and ketoconazole (100 mg/kg/day) alone or in combination by oral route. 196
As can be seen in Figure 6A, controlled. All treatments reduced the parasite load significantly (Fig. 6A -insert) . Nonetheless, no 199 significant differences in serum levels of urea, albumin, ALT, AST, creatinine, bilirubin and 200 creatine kinase were observed in treated and untreated animals, demonstrating that the treatment 201
was not toxic to the mammalian host. Furthermore, no significant change in cholesterol level in 202 serum was observed (Figs. 6B-I) . has been attributed to its immunomodulatory activity (17). 211
Among the active drugs, ezetimibe drew attention due to its property of causing dramatic 212 morphological alterations in the promastigotes (Fig. 1) . These morphological changes are consistent 213 with those previously described as consequence of drug interference in sterol metabolism of 214 trypanosomatids (18-20). In fact, we observed that ezetimibe causes alterations in the sterol 215 composition of the parasites compatible with inhibition of C14-demethylase (21-23). Curiously, 216 ezetimibe is a potent inhibitor of the intestinal cholesterol absorption mediated by the Niemann-217
Pick C1-like 1 protein (NPC1L1) and it is clinically used to reduce cholesterolemia (24). 218
Nevertheless, no inhibition in the human sterol biosynthesis pathway has been described for 219 ezetimibe. However, the sterol pathway of the trypanosomatids has diverged sufficiently to allow 220 selective pharmacological inhibition. Thereby, besides its effect on transport of cholesterol in 221 humans, it is possible that ezetimibe also could interfere with sterol biosynthesis in can be associated to improve their activity (31). Thus, we evaluated the activity of ezetimibe in 227 combination with ketoconazole or miconazole. This association showed synergistic effect on 228 promastigotes (Fig. 2) and increased the activity of these azoles on intracellular amastigotes of L. 229 amazonensis (Figs. 3B and C) . 230
The next step was to evaluate the leishmanicidal activity of ezetimibe alone or combined 231 with ketoconazole in vivo (Figs. 6A and B) . Ezetimibe and ketoconazole alone reduced the lesion 232 growth and parasite load equally in murine model of cutaneous leishmaniasis. The combination was 233 more efficacious in controlling the lesion development, but no difference was observed in parasite 234 burden. Ketoconazole was chosen to be evaluated in vivo because it showed better result on 235 intracellular amastigotes, when in combination with ezetimibe (Fig. 3C) . Moreover, clinical trials 236 have demonstrated that ketoconazole could be advantageous for patients with New World species of 237 Leishmania (32). Oral ketoconazole combined with intra-lesional injections of meglumine 238 antimoniate (Glucantime) has been shown to be more effective than Glucantime alone in the 239 treatment of localized cutaneous leishmaniasis (33). Furthermore, ketoconazole (100 mg/kg/day) 240 reduced splenic parasite load in murine model of visceral leishmaniasis caused by L. infantum, and 241 in the lower dose of 50 mg/kg/day, potentiated the effect of meglumine antimoniate (34). 242
In summary, our screening of FDA approved drugs pointed out ezetimibe as a promising 243 antileishmanial agent. It has antileishmanial activity in vitro and in vivo, supposedly by its effect on 244 parasite sterol biosynthesis, and acts synergistically with azoles. These data suggest that ezetimibe 245 could be useful, in association or not with azoles, in further treatments for leishmaniasis. 246
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